Literature DB >> 31009353

Atrial Fibrillation Known Before or Detected After Stroke Share Similar Risk of Ischemic Stroke Recurrence and Death.

Xiao-Meng Yang1, Zhen-Zhen Rao2, Hong-Qiu Gu3, Xing-Quan Zhao1,3,4, Chun-Juan Wang3,4, Li-Ping Liu5, Chelsea Liu6, Yi-Long Wang1,3,4,7, Zi-Xiao Li1,3, Rui-Ping Xiao2, Yong-Jun Wang1,3,4,7.   

Abstract

Background and Purpose- We aim to compare the risk of 1-year ischemic stroke recurrence and death for atrial fibrillation diagnosed after stroke (AFDAS), atrial fibrillation known before stroke (KAF), and sinus rhythm (SR). Methods- From June 2012 to January 2013, 19 604 patients with acute ischemic stroke were admitted to 219 urban hospitals in the China National Stroke Registry II. Based on heart rhythm assessed during admission, we classified patients as AFDAS, KAF, or SR. We explored the relationship between heart rhythm groups and 1-year ischemic stroke recurrence or death by using Cox regression adjusted for multiple covariates. Considering that death is a competing risk for stroke recurrence, we used the competing risks analysis of Fine and Gray and subdistribution Cox proportional hazards to test the association between heart rhythm and 1-year outcomes. Results- Among 19 604 ischemic stroke patients, 17 727 had SR, 495 AFDAS, and 1382 KAF. At 1 year, 54 (10.9%) patients with AFDAS, 182 (13.2%) with KAF, and 1008 (5.7%) with SR had recurrent ischemic strokes ( P<0.0001). Mortality was 22.0% in patients with AFDAS, 22.1% in patients with KAF, and 7.0% in patients with SR ( P<0.0001). AFDAS-related ischemic stroke recurrence adjusted risk was higher than that of SR (adjusted subdistribution hazard ratios, 1.61; 95% CI, 1.29-2.01) but not different from that of KAF (adjusted subdistribution hazard ratio, 1.12; 95% CI, 0.87-1.45]). The adjusted risk of 1-year death for AFDAS was also higher than that of SR (hazard ratio, 1.70; 95% CI, 1.37-2.12) and not different from that of KAF (hazard ratio, 1.10; 95% CI, 0.86-1.41). Conclusions- This study showed that AFDAS had similar risk of 1-year ischemic stroke recurrence and mortality when compared with KAF and higher risk when compared with SR. The potential risk of AFDAS should be given more emphasis, and appropriate treatment is needed to achieve reduction in the incidence of stroke recurrence and mortality.

Entities:  

Keywords:  atrial fibrillation; ischemic stroke; prognosis; risk; stroke

Mesh:

Year:  2019        PMID: 31009353     DOI: 10.1161/STROKEAHA.118.024176

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

Review 1.  Review and update of the concept of embolic stroke of undetermined source.

Authors:  Hans-Christoph Diener; J Donald Easton; Robert G Hart; Scott Kasner; Hooman Kamel; George Ntaios
Journal:  Nat Rev Neurol       Date:  2022-05-10       Impact factor: 44.711

2.  Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation.

Authors:  David J Seiffge; Gian Marco De Marchis; Masatoshi Koga; Maurizio Paciaroni; Duncan Wilson; Manuel Cappellari; Kosmas Macha Md; Georgios Tsivgoulis; Gareth Ambler; Shoji Arihiro; Leo H Bonati; Bruno Bonetti; Bernd Kallmünzer; Keith W Muir; Paolo Bovi; Henrik Gensicke; Manabu Inoue; Stefan Schwab; Shadi Yaghi; Martin M Brown; Philippe Lyrer; Masahito Takagi; Monica Acciarrese; Hans Rolf Jager; Alexandros A Polymeris; Kazunori Toyoda; Michele Venti; Christopher Traenka; Hiroshi Yamagami; Andrea Alberti; Sohei Yoshimura; Valeria Caso; Stefan T Engelter; David J Werring
Journal:  Ann Neurol       Date:  2020-02-12       Impact factor: 10.422

3.  The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study.

Authors:  Chang-Geng Song; Li-Jie Bi; Jing-Jing Zhao; Xuan Wang; Wen Li; Fang Yang; Wen Jiang
Journal:  Int J Med Sci       Date:  2021-01-09       Impact factor: 3.738

4.  Residual Risk and Its Risk Factors for Ischemic Stroke with Adherence to Guideline-Based Secondary Stroke Prevention.

Authors:  Yuesong Pan; Zixiao Li; Jiejie Li; Aoming Jin; Jinxi Lin; Jing Jing; Hao Li; Xia Meng; Yilong Wang; Yongjun Wang
Journal:  J Stroke       Date:  2021-01-31       Impact factor: 6.967

5.  Clinical Profile of Stroke Patients Presenting to the Emergency Department of a Major Stroke Centre in Oman.

Authors:  Hasina A Al Harthi; Ammar Al Kashmiri; Lubna M Zakaryia; Jawad A Al-Lawati; Omar M Najem; Isra Al-Lawati; Ghulam R Memon; Amr A Elfaham
Journal:  Sultan Qaboos Univ Med J       Date:  2022-02-28

6.  Health outcomes after acute ischemic stroke:retrospective and survival analysis from Oman.

Authors:  Abdullah M Al Alawi; Ikhlas Al Busaidi; Emaad Al Shibli; Al-Reem Al-Senaidi; Shahd Al Manwari; Ibtisam Al Busaidi; Fatema Muhanna; Ahmed Al Qassabi
Journal:  Ann Saudi Med       Date:  2022-08-04       Impact factor: 1.707

7.  Oral anticoagulant decreases stroke recurrence in patients with atrial fibrillation detected after stroke.

Authors:  Jin-Yi Hsu; Peter Pin-Sung Liu; Luciano A Sposato; Huei-Kai Huang; An-Bang Liu; Edward Chia-Cheng Lai; Swu-Jane Lin; Cheng-Yang Hsieh; Ching-Hui Loh
Journal:  Front Cardiovasc Med       Date:  2022-07-22

Review 8.  Stroke-Heart Syndrome: Recent Advances and Challenges.

Authors:  Jan F Scheitz; Luciano A Sposato; Jeanette Schulz-Menger; Christian H Nolte; Johannes Backs; Matthias Endres
Journal:  J Am Heart Assoc       Date:  2022-09-03       Impact factor: 6.106

9.  Phenotypes of atrial fibrillation diagnosed before-versus-after ischaemic stroke and TIA: study protocol for a systematic review and meta-analysis.

Authors:  Amado Jimenez-Ruiz; Juan Camilo Vargas-Gonzalez; Sebastian Fridman; Luciano A Sposato
Journal:  BMJ Open       Date:  2021-07-02       Impact factor: 2.692

10.  Stroke Severity and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation.

Authors:  Kotaro Watanabe; Shuhei Okazaki; Takaya Kitano; Shintaro Sugiyama; Mariko Ohara; Hideaki Kanki; Tsutomu Sasaki; Manabu Sakaguchi; Hideki Mochizuki; Kenichi Todo
Journal:  Front Neurol       Date:  2021-06-29       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.